Cargando…

Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab

Objective: To evaluate humoral and T-cell cellular-mediated immune response after three doses of SARS-CoV-2 mRNA vaccines in patients with systemic lupus erythematosus (SLE) under Belimumab. Patients and methods: 12 patients on Belimumab and 13 age-matched healthy volunteers were recruited. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quartuccio, Luca, De Marchi, Ginevra, Domenis, Rossana, Cabas, Nicola, Guella, Silvia, Paradiso, Antonella, Fabro, Cinzia, Beltrami, Antonio Paolo, De Vita, Salvatore, Curcio, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917399/ https://www.ncbi.nlm.nih.gov/pubmed/36769731 http://dx.doi.org/10.3390/jcm12031083

Ejemplares similares

High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
por: Fabris, Martina, et al.
Publicado: (2022)

Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven et al. Joint Bone Spine 2021;88:105258
por: De Marchi, Ginevra, et al.
Publicado: (2022)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Patient Experiences of Systemic Lupus Erythematosus: Findings From a Systematic Review, Meta‐Summary, and Meta‐Synthesis
por: Petrocchi, Valentina, et al.
Publicado: (2022)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Psychological Effects of Lockdown Measures for the COVID-19 Outbreak in Patients with Systemic Lupus Erythematosus
por: Quartuccio, Luca, et al.
Publicado: (2021)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
por: Zen, Margherita, et al.
Publicado: (2023)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
por: Schwarting, A, et al.
Publicado: (2016)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report
por: Mukkera, Srikanth, et al.
Publicado: (2022)

Short‐term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus
por: Wu, Chunye, et al.
Publicado: (2022)

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review
por: Huang, Shirley P., et al.
Publicado: (2022)

Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus
por: Dashiell-Aje, Ebony, et al.
Publicado: (2017)

Autoimmune Lupus Enteritis with Pan Gastrointestinal Involvement in an Adult Patient with Systemic Lupus Erythematosus: Complete Response to Belimumab
por: Shaik, Mohammed R., et al.
Publicado: (2023)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus
por: Cheng, Hao, et al.
Publicado: (2022)

High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus
por: Maeda, Shinji, et al.
Publicado: (2023)

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
por: Touma, Zahi, et al.
Publicado: (2017)

A Rare Case of Prototheca Algaemia in a Patient with Systemic Lupus Erythematosus and Recent Belimumab Infusion
por: Mejia-Otero, Carolina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u2cksu1e5mrek5vs5fbtij5bbs